GlassScriptPhysician profile
Mark Fisher
NPI 1609961937
$4,057.74
in general payments reported to CMS, 2019-2025
26 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $424 · 2021: $531 · 2022: $705 · 2023: $479 · 2024: $335 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $916.94 | 2019-2025 | Enbrel, Evenity, Prolia |
| Abbvie INC. | $819.09 | 2019-2025 | |
| Janssen Biotech, INC. | $404.55 | 2019-2024 | Tremfya |
| Pfizer INC. | $316.59 | 2019-2024 | |
| Glaxosmithkline, LLC. | $272.93 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $215.74 | 2019-2021 | |
| Ucb, INC. | $175.08 | 2019-2022 | |
| Genentech USA, INC. | $114.60 | 2019-2024 | Actemra |
| Astrazeneca Pharmaceuticals LP | $111.87 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $84.63 | 2019-2020 | |
| Horizon Therapeutics Plc | $70.68 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $66.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.74 | 2021-2025 | Spevigo, Cyltezo |
| Merck Sharp & Dohme LLC | $60.16 | 2019 | |
| Organon LLC | $55.58 | 2022-2023 | Renflexis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $51.80 | 2024-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $49.71 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $43.19 | 2020-2022 | |
| Radius Health, INC. | $41.79 | 2025 | |
| Pacira Therapeutics, INC. | $40.47 | 2019-2020 | |
| Bioventus LLC | $27.92 | 2019 | |
| Aurinia Pharma U.S., INC. | $14.85 | 2022 | |
| Depuy Synthes Sales INC. | $14.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.24 | 2020 | |
| Genzyme Corporation | $12.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.